Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IONS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIonis reports positive 12-month olezarsen data showing liver fat normalizing
Filed June 12, 2026 · Period ending June 12, 2026 · ~1 min read
Key Changes
-
high
Liver fat levels returned toward baseline after 24 months of treatment with 80mg dose, addressing a key safety concern about long-term fat accumulation in the liver.
Item 7.01 view on EDGAR → -
medium
Over 90% of eligible patients from original trials continued into extension study and remained enrolled, suggesting strong tolerability and physician confidence in the drug.
Item 7.01 view on EDGAR → -
medium
Olezarsen maintained favorable safety profile with longer-term treatment in patients with severe hypertriglyceridemia, supporting viability for chronic use.
Item 7.01 view on EDGAR → -
medium
Data presented at National Lipid Association Scientific Sessions from CORE-OLE extension study evaluating olezarsen for severe hypertriglyceridemia.
Item 7.01 view on EDGAR →
Summary
Ionis disclosed positive 12-month results from an ongoing extension study of olezarsen, its drug candidate for severe hypertriglyceridemia. The most significant finding addresses a potential safety concern: liver fat levels that may have increased during treatment returned toward baseline after 24 months on the 80mg dose.
This suggests earlier liver fat changes don't persist long-term, which is critical for a drug intended for chronic use. Retail investors should care because these results strengthen olezarsen's commercial and regulatory prospects. The high patient retention rate (over 90%) indicates real-world acceptance, while the favorable long-term safety profile reduces regulatory risk.
For a company like Ionis that depends on successful drug development, positive late-stage data directly impacts valuation. Watch for regulatory filings and partnership announcements. With strong safety and efficacy data accumulating, Ionis may seek FDA approval or attract a commercial partner willing to pay for rights to the drug. Any updates on the regulatory timeline or deal terms would be the next material catalyst.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Ionis shared positive 12-month data from olezarsen extension study showing liver fat returning toward baseline and high patient retention.
Added in current filing · verify on EDGAR →
On June 12, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) shared positive new data from the open-label extension study of CORE and CORE2 (“CORE-OLE”) evaluating olezarsen in people with severe hypertriglyceridemia (“sHTG”) during an oral presentation at the National Lipid Association Scientific Sessions in Chicago.
Ionis presented new data from an ongoing extension study of olezarsen, a drug for severe hypertriglyceridemia, at a major medical conference. The presentation focused on longer-term results from patients who completed 12 months of treatment in the extension study.
Added in current filing · verify on EDGAR →
Patient retention in the CORE-OLE has been very high, with more than 90% of eligible patients who completed the CORE and CORE2 studies transitioning into and remaining in the CORE-OLE.
More than 90% of eligible patients from the original studies chose to continue in the extension study and remained enrolled. High retention rates suggest patients and physicians view the drug favorably and tolerate it well, which is a positive indicator for commercial potential.
Added in current filing · verify on EDGAR →
Olezarsen continued to demonstrate a favorable safety profile with longer-term treatment.
The drug maintained a favorable safety profile with extended treatment duration. This is important for a chronic therapy where patients would need long-term treatment, and it supports the regulatory and commercial viability of the drug.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 12, 2026 · How we verify